IDH1 and glioblastoma: By inhibiting the DNA repair pathway, PARP-inhibitors enhance cytotoxicity of chemotherapy by inducing excessive accumulation of DNA damage which results in elevated apoptosis observed in PARP-inhibitor treated IDH1 mutant GBM cells [142].